[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","iimxn7z26z2617ntszygbkjeo","revision",2,"title","GSK plc 2026年10月13日购入美国存托凭证","originalTitle","6-K - GSK plc (0001131399) (Filer)","summary","GSK plc 2026年10月13日以每股46.9482美元购入美国存托凭证，涉及326.441至724.875股不等。交易在纽约证券交易所完成，属于股东股息再投资行为。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-15T14:47:26.000Z","discoveredAt","2026-10-15T15:09:12.026Z","timelineAt","category","ai-products","tags",[81],"stockSymbols",[80],"score",22,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fmRhrYy2TPKs",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","284e0d49-0a78-4b26-893d-cf4ef83203b9","GSK高管通过不同方式购入股票",{"_72":73,"_15":74},"zh","

\n\nUNITED STATES

\n\nSECURITIES AND EXCHANGE COMMISSION

\n\nWashington, D.C. 20549

\n\nForm 6-K

\n\nREPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR\n15d-16

\n\nUNDER THE SECURITIES EXCHANGE ACT OF 1934

\nFor the\nmonth of October 2026

\nCommission\nFile Number 001-15170

\n\nGSK plc

\n(Translation\nof registrant's name into English)

\n\n79 New Oxford Street, London, WC1A 1DG

\n(Address\nof principal executive office)

\nIndicate\nby check mark whether the registrant files or will file annual\nreports under cover of Form 20-F or Form 40-F.

\nForm\n20-F . . . .X. . . . Form 40-F . . . . . . . .

\n\nGSK plc (the ‘Company’)

\n\nTransaction notification

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nJames Ford \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nSVP and Group General Counsel, Legal and Compliance \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nAmerican Depositary Shares ('ADS') \n\n \n\nISIN: US37733W2044 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of ADS following the re-investment of dividends paid to\nshareholders on 8 October 2026 \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n$46.9482 \n	\n \n\n326.441 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-13 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nNew York Stock Exchange (XNYS) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nMaya Martinez-Davis \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, US \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nAmerican Depositary Shares ('ADS') \n\n \n\nISIN: US37733W2044 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of ADS following the re-investment of dividends paid to\nshareholders on 8 October 2026 \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n$46.9482 \n	\n \n\n351.842 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-13 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nNew York Stock Exchange (XNYS) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nShobie Ramakrishnan \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nChief Digital and Technology Officer \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nAmerican Depositary Shares ('ADS') \n\n \n\nISIN: US37733W2044 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of ADS following the re-investment of dividends paid to\nshareholders on 8 October 2026 \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n$46.9482 \n	\n \n\n724.875 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-13 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nNew York Stock Exchange (XNYS) \n

\n\nAbout GSK

\n\nGSK is a global biopharma company with a purpose to unite science,\ntechnology, and talent to get ahead of disease together. Find out\nmore at www.gsk.com.

\n\nRegistered in England & Wales:

No.\n3888792

\n\nRegistered Office:

79\nNew Oxford Street

London

WC1A\n1DG

\n\nSIGNATURES

\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf\nby the undersigned, thereunto duly authorised.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n \n\nGSK plc \n
\n\n	\n \n(Registrant) \n
\n\n	\n\n
\n \nDate: October\n15, 2026 \n	\n\n
\n\n	\n\n
\n\n	\n \nBy:/s/ VICTORIA\nWHYTE \n \n-------------------------- \n
\n\n	\n\n
\n\n	\n \nVictoria Whyte \n
\n\n	\n \nAuthorised\nSignatory for and on \n
\n\n	\n \nbehalf\nof GSK plc \n

","zhKind","complete","GSK","其他","aihot","/items/iimxn7z26z2617ntszygbkjeo","https://www.sec.gov/Archives/edgar/data/1131399/000165495426008959/0001654954-26-008959-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]